{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:30:27Z","timestamp":1714782627341},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.amjms.2024.03.022","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T16:03:55Z","timestamp":1711814635000},"update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients"],"prefix":"10.1016","author":[{"given":"Lavisha","family":"Goel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpana","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2024.03.022_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"EHA guidelines committee. Electronic address: guidelines@ehaweb.org; ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2024.03.022_bib0002","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2024.03.022_bib0003","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/jco.jco_43_20","article-title":"Multiple myeloma: an update","volume":"3","author":"Kumar","year":"2020","journal-title":"J Curr Oncol"},{"key":"10.1016\/j.amjms.2024.03.022_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjms.2024.03.022_bib0005","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S1470-2045(18)30447-9","article-title":"The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2024.03.022_bib0006","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosinol","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2024.03.022_bib0007","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2024.03.022_bib0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.amjms.2024.03.022_bib0009","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/cancers12092540","article-title":"Non-hematologic toxicity of bortezomib in multiple myeloma: The neuromuscular and cardiovascular adverse effects","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjms.2024.03.022_bib0010","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2024.03.022_bib0011","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2024.03.022_bib0012","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3109\/10428194.2015.1121258","article-title":"Primary failure of bortezomib in newly diagnosed multiple myeloma\u2013understanding the magnitude, predictors, and significance","volume":"57","author":"Cohen","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.amjms.2024.03.022_bib0013","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.105.005710","article-title":"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib","volume":"33","author":"Uttamsingh","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjms.2024.03.022_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2710.2011.01294.x","article-title":"Distribution of CYP2C19*17 allele and genotypes in an Indian population","volume":"37","author":"Anichavezhi","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.amjms.2024.03.022_bib0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1067\/mcp.2000.109365","article-title":"CYP2C19 genetic mutations in North Indians","volume":"68","author":"Lamba","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjms.2024.03.022_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1472-8206.2004.00307.x","article-title":"CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population","volume":"19","author":"Jose","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.amjms.2024.03.022_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13104-018-3132-0","article-title":"A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients","volume":"11","author":"Hassani Idrissi","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.amjms.2024.03.022_bib0018","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3892\/ol.2015.3294","article-title":"Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma","volume":"10","author":"Zhou","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.amjms.2024.03.022_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-10-404","article-title":"No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma","volume":"10","author":"Vangsted","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.amjms.2024.03.022_bib0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Myeloma Working Group. International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.amjms.2024.03.022_bib0021","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.21105\/joss.03167","article-title":"Visualizations with statistical details: the \u2018ggstatsplot\u2019 approach","volume":"6","author":"Patil","year":"2021","journal-title":"J Open Sourc Softw"},{"key":"10.1016\/j.amjms.2024.03.022_bib0022","first-page":"27","article-title":"Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective","volume":"139","author":"Umamaheswaran","year":"2014","journal-title":"India J Med Res"},{"key":"10.1016\/j.amjms.2024.03.022_bib0023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.amjms.2024.03.022_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003088-200948030-00006","article-title":"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma","volume":"48","author":"Quinn","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924011492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924011492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:16:18Z","timestamp":1714742178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924011492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"alternative-id":["S0002962924011492"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.03.022","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}